Phathom Pharmaceuticals/$PHAT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Ticker
$PHAT
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
427
ISIN
US71722W1071
Website
PHAT Metrics
BasicAdvanced
$300M
-
-$5.19
0.15
-
Price and volume
Market cap
$300M
Beta
0.15
52-week high
$18.68
52-week low
$2.21
Average daily volume
2M
Financial strength
Current ratio
3.578
Quick ratio
3.359
Long term debt to equity
-161.67
Total debt to equity
-166.866
Interest coverage (TTM)
-3.93%
Management effectiveness
Return on assets (TTM)
-55.01%
Return on equity (TTM)
142.04%
Valuation
Price to revenue (TTM)
3.505
Price to book
-0.89
Price to tangible book (TTM)
-0.89
Price to free cash flow (TTM)
-1.015
Growth
Revenue change (TTM)
3,055.71%
Earnings per share change (TTM)
16.45%
3-year earnings per share growth (CAGR)
9.11%
What the Analysts think about PHAT
Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.
PHAT Financial Performance
Revenues and expenses
PHAT Earnings Performance
Company profitability
PHAT News
AllArticlesVideos
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
Seeking Alpha·4 weeks ago
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Phathom Pharmaceuticals stock?
Phathom Pharmaceuticals (PHAT) has a market cap of $300M as of May 30, 2025.
What is the P/E ratio for Phathom Pharmaceuticals stock?
The price to earnings (P/E) ratio for Phathom Pharmaceuticals (PHAT) stock is 0 as of May 30, 2025.
Does Phathom Pharmaceuticals stock pay dividends?
No, Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Phathom Pharmaceuticals dividend payment date?
Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders.
What is the beta indicator for Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.